XENETIC BIOSCIENCES, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
XENETIC BIOSCIENCES, INC. (XBIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-21
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $27.04K, a 23.78% decline from fiscal 2021.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $35.48K, a 26.36% increase from fiscal 2020.
- XENETIC BIOSCIENCES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $28.08K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $7.96K derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $7.96K derived: sum of 3 quarters · filed 2024-03-21 | $17.57K derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $7.96K derived: sum of 2 quarters · filed 2024-03-21 | $17.57K derived: sum of 3 quarters · filed 2024-03-21 | $27.04K 10-K · filed 2024-03-21 |
| 2022-09-30 | $7.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $17.57K derived: sum of 2 quarters · filed 2023-11-09 | $27.04K 10-Q · filed 2023-11-09 | $36.33K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $19.09K 10-Q · filed 2023-08-10 | $28.37K derived: sum of 3 quarters · filed 2023-08-10 | $37.41K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $9.47K 10-Q · filed 2023-05-11 | $18.76K derived: sum of 2 quarters · filed 2023-05-11 | $27.80K derived: sum of 3 quarters · filed 2023-05-11 | $36.54K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $9.28K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $18.32K derived: sum of 2 quarters · filed 2023-03-22 | $27.07K derived: sum of 3 quarters · filed 2023-03-22 | $35.48K 10-K · filed 2023-03-22 |
| 2021-09-30 | $9.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $17.79K derived: sum of 2 quarters · filed 2022-11-09 | $26.20K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $8.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $17.16K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $8.41K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $28.08K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |